Melatonin reversed tumor necrosis factor-alpha-inhibited osteogenesis of human mesenchymal stem cells by stabilizing...

Area of Science:

• Biochemistry
• Cell Biology
• Orthopedics

Background:

• Tumor necrosis factor-alpha (TNFα) significantly contributes to osteoporosis by increasing bone resorption and decreasing bone formation.
• Current osteoporosis treatments primarily inhibit bone resorption, with limited efficacy in enhancing bone formation, crucial for severe bone loss.
• Melatonin exhibits both anti-inflammatory and pro-osteogenic properties, suggesting its potential to counteract TNFα-impaired bone metabolism.

Purpose of the Study:

• To investigate the therapeutic potential of melatonin in reversing TNFα-induced inhibition of osteogenesis in human mesenchymal stem cells.
• To elucidate the molecular mechanisms underlying the interaction between melatonin and TNFα signaling pathways in bone cells.
• To explore the role of SMURF1 and SMAD1 in mediating the effects of melatonin on TNFα-impaired osteogenesis.

Main Methods:

• Utilized human mesenchymal stem cells (hMSCs) to model TNFα-induced osteogenesis inhibition.
• Investigated the effects of melatonin treatment on TNFα-treated hMSCs.
• Analyzed the expression and interaction of SMURF1 and SMAD1 proteins using molecular biology techniques.
• Assessed bone morphogenetic protein (BMP)-SMAD1 signaling pathway activity.

Main Results:

• Melatonin successfully rescued TNFα-inhibited osteogenesis in human mesenchymal stem cells.
• Melatonin treatment downregulated TNFα-induced SMURF1 expression.
• Melatonin reduced SMURF1-mediated ubiquitination and degradation of SMAD1 protein, stabilizing BMP-SMAD1 signaling.
• These molecular changes restored TNFα-impaired osteogenesis.

Conclusions:

• Melatonin demonstrates significant potential for treating osteoporosis associated with inflammation.
• Melatonin's therapeutic effects stem from its ability to regulate bone formation, bone resorption, and inflammation.
• Further research is warranted to explore the precise mechanisms of melatonin's action on SMURF1 and its clinical applicability in bone loss conditions.